SCHEMBL12770646

SCHEMBL12770646

COc1ccc(/C=C/c2cc(OC)c(OC)c(OC)c2)cc1C

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TUBB1 Q9H4B7 14/20 0.81
TUBB4A P04350 9/20 0.69
TUBB P07437 9/20 0.69
TUBA3C P0DPH7 9/20 0.69
TUBA1B P68363 9/20 0.69
TUBA4A P68366 9/20 0.69
TUBB4B P68371 9/20 0.69
TUBB3 Q13509 9/20 0.69
TUBB2A Q13885 9/20 0.69
TUBB8 Q3ZCM7 9/20 0.69
TUBA3E Q6PEY2 9/20 0.69
TUBA1A Q71U36 9/20 0.69
TUBA1C Q9BQE3 9/20 0.69
TUBB6 Q9BUF5 9/20 0.69
TUBB2B Q9BVA1 9/20 0.69
SLC22A2 O15244 1/20 0.68
SLCO2B1 O94956 1/20 0.68
ABCB1 P08183 1/20 0.68
SLC22A6 Q4U2R8 1/20 0.68
SLC22A8 Q8TCC7 1/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9906591 1.00 TUBB1 (0.81) TUBB1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL13813234 0.95 TUBB1 (0.73) TUBB1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL14514240 0.89 TUBB1 (1.00) TUBB1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL5848534 0.87 TUBB1 (0.74) TUBB1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL5848055 0.87 TUBB1 (0.74) TUBB1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL31237302 0.87 TUBB1 (0.74) TUBB1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL12855359 0.87 TUBB1 (0.74) TUBB1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL13763739 0.86 TUBB1 (0.61) TUBB1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL14649649 0.86 TUBB1 (0.68) TUBB1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL12593810 0.86 TUBB1 (0.68) TUBB1TUBB4ATUBBTUBA3CTUBA1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7897820-B2 Process for preparing erianin ZHE JIANG CELL BIOMEDICAL RESEARCH CO., LTD. (CN) 2011-03-01 US disclosed
US-7557096-B2 Synthesis of combretastatin A-4 prodrugs and trans-isomers thereof Arizona Board of Regents, a body corporate of the State of Arizona, acting for an on behalf of the Arizona State University (US) 2009-07-07 US disclosed
US-20090018369-A1 PROCESS FOR PREPARING ERIANIN ZHEJIANG TIANHUANG MEDICINAL PLANT PHARMACEUTICAL CO., LTD. (CN) 2009-01-15 US disclosed
US-7279466-B2 Synthesis of combretastatin A-4 prodrugs and trans-isomers thereof ARIZONA BOARD OF REGENTS (US) 2007-10-09 US disclosed
US-20070203217-A1 SUBSTITUTED STILBENES AND THEIR REACTIONS UNIVERSITEIT UTRECHT UU HOLDING B.V. (NL) 2007-08-30 US disclosed
US-7220784-B2 Substituted stilbenes and their reactions CANCER RESEARCH VENTURES LIMITED (GB) 2007-05-22 US disclosed
US-20070073077-A1 Synthesis of combretastatin A-4 prodrugs and trans-isomers thereof Arizona Board of Regents, a body corporate of the state of Arizona, acting for and on behalf of 2007-03-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070073077-A1 Synthesis of combretastatin A-4 prodrugs and trans-isomers thereof COASY, TMPRSS4, CDK4 TUBB1 2109/4885TUBB4A 532/4885TUBB 2244/4885
US-20070203217-A1 SUBSTITUTED STILBENES AND THEIR REACTIONS CASP4, ATG4B, CTSB TUBB1 1146/4885TUBB4A 568/4885TUBB 1056/4885
US-20090018369-A1 PROCESS FOR PREPARING ERIANIN ERLIN1, ERLIN2, EI24 TUBB1 2267/4885TUBB4A 541/4885TUBB 2033/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.